stoxline Quote Chart Rank Option Currency Glossary
  
Adagene Inc. (ADAG)
1.96  0.1 (5.38%)    02-19 13:22
Open: 1.9
High: 2.05
Volume: 51,360
  
Pre. Close: 1.86
Low: 1.9
Market Cap: 87(M)
Technical analysis
2025-02-19 12:47:35 PM
Short term     
Mid term     
Targets 6-month :  2.47 1-year :  2.89
Resists First :  2.11 Second :  2.47
Pivot price 1.82
Supports First :  1.82 Second :  1.63
MAs MA(5) :  1.84 MA(20) :  1.83
MA(100) :  2.2 MA(250) :  2.51
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  65.7 D(3) :  46.5
RSI RSI(14): 59.2
52-week High :  3.65 Low :  1.63
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ADAG ] has closed It is unclear right now based on current values. 49.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.92 - 1.93 1.93 - 1.94
Low: 1.79 - 1.8 1.8 - 1.81
Close: 1.89 - 1.91 1.91 - 1.92
Company Description

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Headline News

Sun, 16 Feb 2025
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat

Thu, 13 Feb 2025
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Thu, 13 Feb 2025
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World

Tue, 04 Feb 2025
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat

Mon, 27 Jan 2025
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan

Tue, 21 Jan 2025
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 44 (M)
Held by Insiders 2.034e+007 (%)
Held by Institutions 11.3 (%)
Shares Short 80 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.613e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 534.8 %
Return on Equity (ttm) -19.6 %
Qtrly Rev. Growth 815750 %
Gross Profit (p.s.) 0
Sales Per Share -87.89
EBITDA (p.s.) 1.56875e+006
Qtrly Earnings Growth -0.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -28 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0.81
Stock Dividends
Dividend 0
Forward Dividend 35440
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android